Click on image or enlarge button to enlarge
6-Diazo-5-oxo-L-norleucine: sc-227078
6-Diazo-5-oxo-L-norleucine (CAS 157-03-9)
Alternate Names:
DON
Application:
6-Diazo-5-oxo-L-norleucine is a glutamine analogue
CAS Number:
157-03-9
Purity:
≥95%
Molecular Weight:
171.15
Molecular Formula:
C6H9N3O3
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
6-Diazo-5-oxo-L-norleucine, a glutamine analogue, inhibits glutamine flux between cells. It is used as an inhibitor to study the function, specificity and characteristics of cytidine triphosphate synthase 1s (CTPS1) and various glutaminases.
References:
- Antiviral effect of 6-diazo-5-oxo-L-norleucine, antagonist of gamma-glutamyl transpeptidase, on replication of human parainfluenza virus type 2. | Nishio, M., et al. 1990. J Gen Virol. 71 (Pt 1): 61-7. PMID: 1968085
- Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry. | Alt, J., et al. 2015. Anal Biochem. 474: 28-34. PMID: 25584882
- Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo-l-Norleucine in Mice with Alphavirus Encephalomyelitis. | Manivannan, S., et al. 2016. J Virol. 90: 9251-62. PMID: 27489275
- Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. | Rais, R., et al. 2016. J Med Chem. 59: 8621-33. PMID: 27560860
- Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer. | Cervantes-Madrid, D., et al. 2017. Oncol Lett. 13: 1905-1910. PMID: 28454342
- Evaluation of genetic toxicity of 6-diazo-5-oxo-l-norleucine (DON). | Kulkarni, RM., et al. 2017. Toxicol Mech Methods. 27: 518-527. PMID: 28552037
- Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs. | Tenora, L., et al. 2019. J Med Chem. 62: 3524-3538. PMID: 30892035
- Transient meiotic arrest maintained by DON (6-diazo-5-oxo-l-norleucine) enhances nuclear/cytoplasmic maturation of porcine oocytes. | Yang, HJ., et al. 2019. Reproduction. 158: 543-554. PMID: 31652418
- L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells. | Ohba, S. and Hirose, Y. 2020. J Neurooncol. 146: 469-475. PMID: 32020477
- Complete Biosynthetic Pathway of Alazopeptin, a Tripeptide Consisting of Two Molecules of 6-Diazo-5-oxo-l-norleucine and One Molecule of Alanine. | Kawai, S., et al. 2021. Angew Chem Int Ed Engl. 60: 10319-10325. PMID: 33624374
- Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. | Xiang, J., et al. 2021. J Clin Invest. 131: PMID: 33690219
- Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor. | Gao, RD., et al. 2021. Bioorg Med Chem Lett. 50: 128321. PMID: 34400301
- Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation. | Yu, Q., et al. 2022. Front Immunol. 13: 880262. PMID: 35663990
- Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site. | Shapiro, RA., et al. 1979. J Biol Chem. 254: 2835-8. PMID: 429321
- Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase. | Rosenfeld, H. and Roberts, J. 1981. Cancer Res. 41: 1324-8. PMID: 7214322